A Measurement of the Millimeter Emission and the Sunyaev-Zel'dovich Effect Associated with Low-Frequency Radio Sources

We present a statistical analysis of the millimeter-wavelength properties of 1.4 GHz-selected sources and a detection of the Sunyaev-Zel'dovich effect associated with the halos that host them. We stack data at 148, 218 and 277 GHz from the Atacama Cosmology Telescope at the positions of a large sample of radio AGN selected at 1.4 GHz. The thermal Sunyaev-Zel'dovich (SZ) effect associated with the halos that host the AGN is detected at the 5 sigma level through its spectral signature, representing a statistical detection of the SZ effect in some of the lowest mass halos (average M(sub 200) approximately equals 10(sup 13) solar mass h(sub 70)(exp 1) ) studied to date. The relation between the SZ effect and mass (based on weak lensing measurements of radio galaxies) is consistent with that measured by Planck for local bright galaxies. In the context of galaxy evolution models, this study confirms that galaxies with radio AGN also typically support hot gaseous halos. Adding Herschel observations allows us to show that the SZ signal is not significantly contaminated by dust emission. Finally, we analyze the contribution of radio sources to the angular power spectrum of the cosmic microwave background

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial. The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015. This article is an update of the 2015 guidelines.Meeting and production costs have been covered by MASCC and ESMO from central funds.https://www.esmoopen.comhj2024ImmunologySDG-03:Good heatlh and well-bein

A Randomized Trial of the Electronic Lung Cancer Symptom Scale for Quality-of-Life Assessment in Patients with Advanced Non-small-Cell Lung Cancer

Introduction: Improving health-related quality of life (hrqol) is a key goal of systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact of a real-time electronic hrqol tool, the electronic Lung Cancer Symptom Scale (elcss-ql), on palliative care (pc) referral rates, patterns of chemotherapy treatment, and use of other supportive interventions in patients with advanced non-small-cell lung cancer (nsclc) receiving first-line chemotherapy. Methods: Patients with advanced nsclc starting first-line chemotherapy were randomized to their oncologist receiving or not receiving their elcss-ql data before each clinic visit. Patients completed the elcss-ql at baseline, before each chemotherapy cycle, and at subsequent follow-up visits until disease progression. Prospective data about the pc referral rate, hrqol, and use of other supportive interventions were collected. Results: For the 95 patients with advanced nsclc who participated, oncologists received real-time elcss-ql data for 44 (elcss-ql arm) and standard clinical assessment alone for 51 (standard arm). The primary endpoint, the pc referral rate, was numerically higher, but statistically similar, for patients in the elcss-ql and standard arms. The hrqol scores over time were not significantly different between the two study arms. Conclusions: The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and hrqol should be an important component of care for patients with advanced lung cancer